Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07062119 in Advanced Gastrointestinal Tumors
NCT04171141Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Nov 2019
- Primary completion
- Nov 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of PF-07062119 in colorectal adenocarcinoma, gastric adenocarcinoma and esophageal adenocarcinoma (EAC) (7 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Dose Limiting Toxicities (DLTs) at 28 Days, Number of Participants With All-Causality Treatment-Emergent Adverse Events at 4 Years and 3 more. Started Nov 2019; status: terminated.
02
Drugs
PF-07062119
03
Conditions
colorectal adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT04171141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171141.